Mutual of America Capital Management LLC increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.2% during the first quarter, Holdings Channel reports. The institutional investor owned 202,117 shares of the biopharmaceutical company’s stock after buying an additional 11,791 shares during the period. Mutual of America Capital Management LLC’s holdings in Gilead Sciences were worth $13,728,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the company. Hall Laurie J Trustee raised its stake in Gilead Sciences by 20.0% in the first quarter. Hall Laurie J Trustee now owns 1,500 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 250 shares in the last quarter. Cable Hill Partners LLC raised its stake in Gilead Sciences by 51.9% in the first quarter. Cable Hill Partners LLC now owns 1,584 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 541 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. raised its stake in Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 1,400 shares in the last quarter. Dubuque Bank & Trust Co. raised its stake in Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 267 shares in the last quarter. Finally, Webster Bank N. A. raised its stake in Gilead Sciences by 51.7% in the first quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock valued at $125,000 after buying an additional 624 shares in the last quarter. Institutional investors and hedge funds own 73.99% of the company’s stock.

Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at 73.16 on Friday. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $82.10. The firm has a market cap of $95.55 billion, a price-to-earnings ratio of 7.95 and a beta of 1.21. The firm has a 50-day moving average price of $70.60 and a 200-day moving average price of $68.59.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.11 by $0.45. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The company had revenue of $7.14 billion during the quarter, compared to the consensus estimate of $6.35 billion. During the same quarter in the prior year, the business earned $3.08 earnings per share. The company’s revenue was down 8.2% compared to the same quarter last year. Analysts predict that Gilead Sciences, Inc. will post $8.76 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Stockholders of record on Friday, September 15th will be given a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 2.84%. The ex-dividend date of this dividend is Thursday, September 14th. Gilead Sciences’s payout ratio is 22.58%.

ILLEGAL ACTIVITY NOTICE: “Mutual of America Capital Management LLC Buys 11,791 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)” was originally published by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The legal version of this report can be accessed at https://www.dailypolitical.com/2017/08/05/mutual-of-america-capital-management-llc-buys-11791-shares-of-gilead-sciences-inc-nasdaqgild.html.

GILD has been the topic of several recent research reports. Vetr lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $74.88 price objective on the stock. in a research report on Tuesday, April 25th. Stifel Nicolaus restated a “buy” rating and issued a $87.00 price objective on shares of Gilead Sciences in a research report on Monday, April 24th. Zacks Investment Research raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $76.00 target price for the company in a research note on Tuesday, May 2nd. Piper Jaffray Companies reaffirmed a “buy” rating on shares of Gilead Sciences in a research note on Friday, April 21st. Finally, Cowen and Company reaffirmed a “buy” rating and set a $100.00 target price on shares of Gilead Sciences in a research note on Monday, April 17th. Eleven equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $80.31.

In other news, EVP Gregg H. Alton sold 5,000 shares of the company’s stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $71.06, for a total value of $355,300.00. Following the completion of the sale, the executive vice president now owns 102,988 shares of the company’s stock, valued at $7,318,327.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director John Francis Cogan sold 9,943 shares of the company’s stock in a transaction dated Tuesday, May 9th. The stock was sold at an average price of $67.25, for a total value of $668,666.75. Following the completion of the sale, the director now directly owns 47,562 shares of the company’s stock, valued at approximately $3,198,544.50. The disclosure for this sale can be found here. Insiders sold 216,609 shares of company stock valued at $15,891,851 in the last ninety days. Company insiders own 1.30% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.